| 1 |
32606016 | Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. | 2020 Sep |
2 |
| 2 |
32736668 | Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis. | 2020 Aug 27 |
1 |
| 3 |
30739792 | Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer. | 2019 Mar 19 |
1 |
| 4 |
29112301 | Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. | 2018 Jan |
1 |
| 5 |
30174840 | Genetic and pharmacological inhibition of eIF4E effectively targets esophageal cancer cells and augments 5-FU's efficacy. | 2018 Jul |
1 |
| 6 |
27932243 | Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma. | 2017 Jan 22 |
4 |
| 7 |
26317515 | Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. | 2015 |
1 |
| 8 |
19619545 | Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. | 2009 Sep 3 |
8 |